Gold JM - Search Results

1

The Cognitive and Negative Symptoms in Schizophrenia Trial (CONSIST): the efficacy of glutamatergic agents for negative symptoms and cognitive impairments.

Buchanan RW, Javitt DC, Marder SR, Schooler NR, Gold JM, McMahon RP, Heresco-Levy U, Carpenter WT. Buchanan RW, et al. Among authors: gold jm. Am J Psychiatry. 2007 Oct;164(10):1593-602. doi: 10.1176/appi.ajp.2007.06081358. Am J Psychiatry. 2007. PMID: 17898352 Clinical Trial.

2

Lack of sex differences in the neuropsychological performance of patients with schizophrenia.

Goldberg TE, Gold JM, Torrey EF, Weinberger DR. Goldberg TE, et al. Among authors: gold jm. Am J Psychiatry. 1995 Jun;152(6):883-8. doi: 10.1176/ajp.152.6.883. Am J Psychiatry. 1995. PMID: 7755118

3

Contrasts between patients with affective disorders and patients with schizophrenia on a neuropsychological test battery.

Goldberg TE, Gold JM, Greenberg R, Griffin S, Schulz SC, Pickar D, Kleinman JE, Weinberger DR. Goldberg TE, et al. Among authors: gold jm. Am J Psychiatry. 1993 Sep;150(9):1355-62. doi: 10.1176/ajp.150.9.1355. Am J Psychiatry. 1993. PMID: 8352346

4

Negative symptoms: diagnosis, treatment and prognosis.

Buchanan RW, Gold JM. Buchanan RW, et al. Among authors: gold jm. Int Clin Psychopharmacol. 1996 May;11 Suppl 2:3-11. doi: 10.1097/00004850-199605002-00002. Int Clin Psychopharmacol. 1996. PMID: 8803654 Review.

5

The role of negative symptoms and cognitive dysfunction in schizophrenia outcome.

Tamminga CA, Buchanan RW, Gold JM. Tamminga CA, et al. Among authors: gold jm. Int Clin Psychopharmacol. 1998 Mar;13 Suppl 3:S21-6. doi: 10.1097/00004850-199803003-00004. Int Clin Psychopharmacol. 1998. PMID: 9690966 Review.

6

Cognitive rehabilitation for schizophrenia: problems, prospects, and strategies.

Bellack AS, Gold JM, Buchanan RW. Bellack AS, et al. Among authors: gold jm. Schizophr Bull. 1999;25(2):257-74. doi: 10.1093/oxfordjournals.schbul.a033377. Schizophr Bull. 1999. PMID: 10416730 Review.

7

Prediction of neuropsychological performance by neurological signs in schizophrenia.

Arango C, Bartko JJ, Gold JM, Buchanan RW. Arango C, et al. Among authors: gold jm. Am J Psychiatry. 1999 Sep;156(9):1349-57. doi: 10.1176/ajp.156.9.1349. Am J Psychiatry. 1999. PMID: 10484944

8

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia I: sensitivity, reliability, and validity.

Gold JM, Queern C, Iannone VN, Buchanan RW. Gold JM, et al. Am J Psychiatry. 1999 Dec;156(12):1944-50. doi: 10.1176/ajp.156.12.1944. Am J Psychiatry. 1999. PMID: 10588409

9

Repeatable battery for the assessment of neuropsychological status as a screening test in schizophrenia, II: convergent/discriminant validity and diagnostic group comparisons.

Hobart MP, Goldberg R, Bartko JJ, Gold JM. Hobart MP, et al. Among authors: gold jm. Am J Psychiatry. 1999 Dec;156(12):1951-7. doi: 10.1176/ajp.156.12.1951. Am J Psychiatry. 1999. PMID: 10588410

10

Decisional capacity for informed consent in schizophrenia research.

Carpenter WT Jr, Gold JM, Lahti AC, Queern CA, Conley RR, Bartko JJ, Kovnick J, Appelbaum PS. Carpenter WT Jr, et al. Among authors: gold jm. Arch Gen Psychiatry. 2000 Jun;57(6):533-8. doi: 10.1001/archpsyc.57.6.533. Arch Gen Psychiatry. 2000. PMID: 10839330

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

393 results

Search Page